Drugs and Chronic Viral Hepatitis
This is a medicinal age. Indeed, it appears that it has always been so, because human kind, even in antiquity and prehistoric times, appears to have been fascinated with exogenous chemicals and xenobiotics that affect the mind and body. However, advances in therapeutics have been truly remarkable within the past one or two generations. Increasingly, new drugs are being developed, based on biochemical and structural knowledge of specific targets, such as site-directed inhibitors of enzymes in host human beings, or in infectious agents. Other drugs are targeted at specific receptors such as the histamine type- 1 and -2 receptors, the several types of serotonin receptors, and so on.
KeywordsLiver Disease Chronic Hepatitis Chronic Liver Disease Herbal Remedy Chronic Viral Hepatitis
Unable to display preview. Download preview PDF.
- 2.Hoyumpa AM, Schenker S. Influence of liver disease on the disposition and elimination of drugs. In: Diseases of the Liver (Schiff L, Schiff ER, eds.), 7th ed. Philadelphia: JB Lippincott 1993. pp. 784–824.Google Scholar
- 8.MaherJ.Alcoholicliverdisease.In:GastrointestinalandLiverDisease(Sleisenger MH, Fordtran JS, eds.), 6th ed. Philadelphia: Saunders, 1998, pp. 1199–1202.Google Scholar
- 12.Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 1988; 88: 1337–1345.Google Scholar
- 14.Barton JC, Edwards CQ, eds. Part V of Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge UK: Cambridge University Press, 2000, pp. 229–328.Google Scholar
- 20.Farrell, GC. Drug Induced Liver Disease. Melbourne: Churchill Livingstone, 1994.Google Scholar
- 22.Niwa T, Sato R, Yabusaki Y, et al. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 1999; 29: 1 87–193.Google Scholar
- 30.Dorr RT. Interferon-alpha in malignant and viral diseases. A review. Drugs 1993; 45: 177–211.Google Scholar
- 36.Di Bisceglie AM, Bacon BR, Kleiner DE, et al. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994• 21• 1109–1112Google Scholar
- 37.Fiel MI, Schiano TD, Guido M, et al. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am J Clin Pathol 2000; 113: 35–39.SGoogle Scholar
- 39.Bonkovsky HL, Stefancyk D, Tortorelli K, et al. Comparative effects of different doses of ribavirin (600 vs. 1000–1200 mg per day) plus interferon alpha-2b for therapy of chronic hepatitis C: results of a controlled, randomized trial, submitted, 2000.Google Scholar
- 41.Hanna GJ, Hirsch MS. Antiretroviral therapy of human immunodeficiency virus infection. In: Principles and Practice of Infectious Diseases (Mandell GL, Bennett JE, Dolin R, eds.), 5th ed. Philadelphia: Churchill Livingstone, 2000, pp. 1479–1499.Google Scholar